This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

RFA (Radiofrequency Ablation) Versus EA (Ethanol Ablation) for Predominantly Cystic Thyroid Nodules

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified November 2013 by Jung Hwan Baek, Asan Medical Center.
Recruitment status was:  Enrolling by invitation
Information provided by (Responsible Party):
Jung Hwan Baek, Asan Medical Center Identifier:
First received: January 25, 2013
Last updated: November 7, 2013
Last verified: November 2013
Ultrasound-guided ethanol ablation is an effective treatment modality for patients with cystic thyroid nodules (cystic portion > 90%); however it is less effective in predominantly cystic thyroid nodules (90% > cystic portions > 50%). The volume reduction after EA has been reported 64% - 69.8% for predominantly cystic thyroid nodules. EA is insufficient for 26% (27/103) of patients with predominantly cystic thyroid nodules. Radiofrequency ablation to patients with incompletely resolved clinical problems after EA and the mean volume reduction ratio was 92% at 6-month follow-up. It is well known that RF ablation is effective in both predominantly cystic and solid thyroid nodules. Although RF ablation has effectively treated the patients who were unsatisfactory after EA, to the best of our knowledge, no study to date has compared these two ablation techniques. Therefore investigators performed a prospective randomized study to compare single-session RF ablation and EA for treating predominantly cystic thyroid nodules.

Condition Intervention
Thyroid Nodule Procedure: radiofrequency ablation Procedure: Ethanol ablation

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Single Session Treatment of RFA Versus EA for Predominantly Cystic Thyroid Nodules: A Randomized Controlled Trial

Resource links provided by NLM:

Further study details as provided by Jung Hwan Baek, Asan Medical Center:

Primary Outcome Measures:
  • quantitative volume reduction ratio of a thyroid lesion at six months following compared with before the ablation treatment [ Time Frame: at six months following compared with before the ablation treatment ]

Secondary Outcome Measures:
  • binary therapeutic success rate which was defined as the proportion of patients who showed volume reduction >50%, improvement of symptomatic and cosmetic scores, and the number of major complications [ Time Frame: 6-month ]

Estimated Enrollment: 50
Study Start Date: February 2013
Estimated Study Completion Date: January 2014
Primary Completion Date: May 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Radiofrequency ablation
Treatment with radiofrequency ablation for the thyroid lesions and compare the results with ethanol ablation in terms of volume reduction at 6-month follow-up (primary end point).
Procedure: radiofrequency ablation
radiofrequency ablation for the treatment as a new therapy as compared with ethanol ablation as a conventional therapy
Active Comparator: Ethanol
Treatment of predominantly cystic nodule with ethanol ablation and compare these results to radiofrequency ablation in terms of volume reduction at 6-month follow-up.
Procedure: Ethanol ablation
ethanol ablation as a conventional/control therapy to be compared with a new experimental therapy--radiofrequency ablation

  Show Detailed Description


Ages Eligible for Study:   20 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • patients with predominantly cystic thyroid nodules (90% > cystic portion > 50%)
  • reports of pressure symptoms or cosmetic problems
  • cytologic confirmation of benignancy in at least two, separate US-guided, fine-needle aspiration cytology or core needle biopsy for cystic fluid and/or a mural, solid component
  • serum levels of thyroid hormone, thyrotropin, and calcitonin within normal limits.

Exclusion Criteria:

  • nodules showing malignant features, i.e. taller than wide, spiculated margin, markedly hypoechoic, micro- or macrocalcifications, on US
  • lack of informed consent
  • less than 20 years old
  • pregnant woman
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01778400

Korea, Republic of
Asan Medical Center
Seoul, Korea, Republic of, 138-736
Sponsors and Collaborators
Asan Medical Center
Study Chair: Jung Hwan Baek, MD Asan Medical Center
  More Information

Responsible Party: Jung Hwan Baek, Associate professor, Asan Medical Center Identifier: NCT01778400     History of Changes
Other Study ID Numbers: BJH_PCYST
Study First Received: January 25, 2013
Last Updated: November 7, 2013

Keywords provided by Jung Hwan Baek, Asan Medical Center:
Predominantly cystic thyroid nodule
Thyroid nodule

Additional relevant MeSH terms:
Thyroid Diseases
Thyroid Nodule
Endocrine System Diseases
Thyroid Neoplasms
Endocrine Gland Neoplasms
Neoplasms by Site
Head and Neck Neoplasms
Anti-Infective Agents, Local
Anti-Infective Agents
Central Nervous System Depressants
Physiological Effects of Drugs processed this record on August 18, 2017